Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer

Condition(s) targeted: Breast Cancer

Intervention: Abraxane (Drug)

Phase: N/A

Status: Active, not recruiting

Sponsored by: Dana-Farber Cancer Institute

Official(s) and/or principal investigator(s):
Harold Burstein, MD, Principal Investigator, Affiliation: Dana-Farber Cancer Institute

The purpose of this trial is to see if Abraxane, which is a new form of paclitaxel, is safe as a replacement form of paclitaxel in dose-dense chemotherapy. This trial will also determine if using Abraxane will allow patients to receive treatment every two weeks without requiring injects of G-CSF, a white blood cell stimulating growth factor.

Official title: Dose Dense AB1-007 (Abraxane) in Adjuvant Chemotherapy for Breast Cancer: A Feasibility Study

Study design: Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study

Primary outcome: To evaluate the feasibility and toxicity of Abraxane after chemotherapy as part of dose-dense adjuvant chemotherapy for breast cancer.

Secondary outcome:

To evaluate the feasibility of administering Abraxane on a dose dense schedule without G-CSF support

to estimate the percentage of patients with various grades of hematologic toxicity, neurotoxicity, and other non-hematologic toxicity associated with dose-dense Abraxane

to evaluate quality of life.

Detailed description:

- Patients will receive regular chemotherapy every 2 weeks for up to 8 cycles

(approximately 16 weeks total)of treatment. During the first four cycles patients will be treated with Adriamycin and Cytoxan, and for the second four cycles they will be treated with Abraxane.

- Patients will be taught to give themselves injections with either short or long acting

G-CSF as prescribed by their doctor for the first four cycles of chemotherapy. During the last four cycles (while the patient is taking Abraxane) they will not receive G-CSF unless they have low blood counts.

- If the patient has HER-2 positive breast cancer, they will also receive 52 weeks of

Herceptin as part of standard cancer care and will begin to receive Herceptin at the same time they begin Abraxane (after 4 cycles of adriamycin and cytoxan treatment).

- This study involves a series of Quality of Life Questionnaires that will be completed

prior to beginning study treatment, then again at 2 months, 4 months, 6 months, and 1 year after starting study treatment.

- The following tests and procedures will be performed at the time periods specified.

Cycle 1-4 Day 1: Physical exam, vital signs, and blood tests. Cycle 5 Day 1: Physical exam, vital signs, blood tests, RVG (measurement of heart function) and questionnaire. Cycle 6 & 7 Day 1: Physical exam, vital signs, and blood tests. Cycle 8 Day 1: physical exam, vital signs, blood tests, questionnaire. Follow-up (6 months and 1 year after cycle 1 day 1): questionnaire.

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Histologically or cytologically confirmed breast cancer, with clinical stage I, II, or

III disease

- Must register at the beginning of adjuvant or neoadjuvant chemotherapy

- 18 years of age or older

- ECOG performance status of 0 or 1

- Normal organ and marrow function

Exclusion Criteria:

- Previous cytotoxic chemotherapy or therapeutic radiation therapy for any reason

- Pregnant or nursing

- Receiving any other investigational agents

- Patients with Stage IV breast cancer

- Current grade II or greater peripheral neuropathy or prior history of grade II or

greater neuropathy

- Uncontrolled intercurrent illness, including but not limited to, ongoing or active

infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrythmia, or psychiatric illness/social situations that would limit compliance with study requirements

- Immune deficiency when treated with marrow-suppressive therapy or HIV-positive

patients receiving anti-retroviral therapy

- Patients with sickle cell disease

- Known history of hyperviscosity syndrome

- Patients on lithium

Dana-Farber Cancer Institute, Boston, Massachusetts 02115, United States

Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, United States

Massacusetts General Hospital, Boston, Massachusetts 02114, United States

Starting date: March 2006
Ending date: March 2010
Last updated: December 19, 2007